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Abstract 
Several recent reports have described associations between gestational diabetes 
(GDM) and changes to the epigenomic landscape where the DNA samples were 
derived from either cord or placental sources. We employed genome-wide 450Karray 
 3 
 
analysis to determine changes to the epigenome in a unique cohort of maternal blood 
DNA from 11 pregnant women prior to GDM development relative to matched controls. 
Hierarchical clustering segregated the samples into two distinct clusters comprising 
GDM and healthy pregnancies. Screening identified 100 CpGs with a mean β-value 
difference of ≥0.2 between cases and controls. Using stringent criteria, 5 CpGs (within 
COPS8, PIK3R5, HAAO, CCDC124, and C5orf34 genes) demonstrated potentials to 
be clinical biomarkers as revealed by differential methylation in 8 of 11 women who 
developed GDM relative to matched controls. We identified, for the first time, maternal 
methylation changes prior to the onset of GDM that may prove useful as biomarkers 
for early therapeutic intervention. 
 
Keywords: gestational diabetes, epigenetics, fetal programming, biomarker, 450K 
array 
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Introduction 
Gestational diabetes (GDM) is a pregnancy-specific endocrine disorder with a 
prevalence of 3.5-14%.1 Due to the worldwide obesity epidemic and recently modified 
diagnostic criteria, GDM is increasingly prevalent.2 It occurs because of a mismatch 
between insulin production and requirement, leading to maternal hyperglycemia. 
Since glucose is able to cross the placenta, whereas insulin is not, the fetus is also 
exposed to hyperglycemic conditions. Women with GDM are at increased risk of 
caesarean section and stillbirth compared with healthy women.3, 4 They are also more 
likely to develop type 2 diabetes (T2DM), dyslipidemia, and cardiovascular disease in 
later life,5-7 while their offspring have an increased long-term risk of obesity and 
diabetes.2 
 
Epigenetic modifications, which may be causal of or associated with changes in gene 
expression, offer significant promise for understanding the underlying mechanisms of 
GDM. Indeed, and as an example, epigenetic changes in T2DM have been reported 
in genes involved in metabolism.8-13 Since maternal epigenetic modifications are 
known to contribute to fetal programming,14 recent studies have investigated the role 
of epigenetic alterations in offspring exposed to maternal hyperglycemia and found 
positive associations.15-19 Furthermore, previous studies suggest that epigenetic 
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modifications may play a role in the pathogenesis of GDM.20, 21 
 
Epigenetic research in GDM has largely used targeted (candidate gene) 
approaches.15, 16, 18, 19 To date, only two studies have utilized genome-wide 
methodology17, 22 and in these cases investigators examined placenta and cord blood 
samples from GDM pregnancies. Differentially methylated genes were identified 
between GDM and healthy pregnancies,17, 22 which provide evidence for the 
involvement of these genes and/or their differential methylation in GDM. However, 
there have been no genome-wide studies examining methylation differences between 
maternal tissue samples from GDM and healthy pregnancies. We decided to focus on 
maternal epigenetic profiles, as they would facilitate the assessment of the in utero 
environment and allow identification of predictive biomarkers that would enable 
targeted intervention to high risk groups. 
 
On the basis of the current literature, we hypothesized the presence of pre-existing 
epigenetic markers in women who subsequently go on to develop GDM. In this study, 
and for the first time in this disease, we interrogated genome-wide DNA methylation in 
peripheral blood samples collected from women prior to the development of GDM and 
relative to matched healthy controls that did not develop GDM. Using this discovery 
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cohort, our aim was to identify candidate genes with future promise as potential 
biomarkers for the prediction of GDM in early pregnancy. 
 
Results 
Our initial data analyses focused on comparison of our data in antenatal samples with 
the two recent genome-wide studies that investigated cord blood and placental tissue 
samples.17, 22 We compared our data with those of Finer et al.22 and Ruchat et al.17 
separately due to the different approaches used for data processing by each study 
(Figure 1). Using the filtering criteria shown in step 1A of Figure 1, comparison of our 
data with those of Finer et al.22 identified 4,755 differentially methylated CpGs 
(representing 2,236 genes) where the mean β-value difference between the GDM and 
healthy groups was >0.05 and statistically significant (P<0.05). In contrast, 
comparison with the data of Ruchat et al.17 (step 1B of Figure 1) identified 1,035 
CpGs (representing 633 candidate genes). We also performed the same comparison 
after applying multiple testing adjustment using the false discovery rates, which 
showed no overlap of our data with these two studies.  
 
As shown in Figure 2A, by comparing the 2,236 genes identified as differentially 
methylated in our study with those reported by Finer et al.,22 two genes were common 
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between maternal blood, umbilical cord, and placenta: Hook Microtubule-Tethering 
Protein 2 (HOOK2) and Retinol Dehydrogenase 12 (RDH12). Conversely, and as 
summarized by the Venn diagram in Figure 2B, there were no genes common to all 
three tissue types when we compared our data with that of Ruchat et al.17  
 
The 4,755 CpGs initially identified as differentially methylated were then subjected to 
further filtering (steps 2 and 3, Figure 1). Using this approach, we identified 100 
unique CpGs (comprising 66 genes) that were differentially methylated between GDM 
and healthy pregnancies (the full annotated list is shown in Table S1). None of these 
CpGs have an annotated single-nucleotide polymorphism (SNP) in the probe. Closer 
examination of the 100 CpGs revealed that the majority (53%) were hypomethylated 
in GDM relative to healthy pregnancies. The observed differences in mean β-value 
showed a maximum difference of 0.38. The frequency and DNA methylation of these 
differentially methylated CpG sites in relation to their genomic location and CpG 
islands are shown in Figure S1. Of the differentially methylated CpGs, 45% were 
associated with a CpG island, shelf, or shore (Figure S1C). 
 
Hierarchical clustering was performed to determine whether the methylation patterns 
in these 100 CpGs can be used to distinguish between GDM and healthy pregnancies. 
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The heatmap in Figure 3 illustrates that there are distinctive methylation patterns 
between GDM and healthy pregnancies, which segregate samples into two distinct 
groups comprising those from GDM and healthy populations. The slide type did not 
cause the clustering; therefore, our results were not due to batch effects. Calculation 
of the genomic inflation factor before and after normalization steps showed that 
removal of SNP containing probes and subset-quantile within array normalization 
(SWAN) by the minfi package reduced the genomic inflation.23-25 Pre-normalization λ 
was estimated to be 1.189 (standard error of the estimation = 9.461 x 10-5); after 
normalization, the estimated λ was reduced to 1.132 (standard error of the estimation 
= 7.461 x 10-5). The remaining genomic inflation suggests that mild 
confounding stratification factors remain unaccounted for in the data.  
 
Enrichment of gene ontology terms and biological pathways within the 66 genes 
associated with differentially methylated CpGs were assessed using DAVID online 
software26 and identified 11 overrepresented pathways, with the top three (ranked by 
P-value) involved in cell adhesion molecules, type 1 diabetes mellitus, and keratin 
pathways. However, enrichment of these pathways was not statistically significant 
following adjustment for false discovery rates (Table S2). 
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Finally, we examined the absolute β-value differences across all 11 matched pairs. 
Using this stringent criteria, in 5 of the 100 CpGs identified, at least 8 of the 11 GDM 
pregnancies showed β-value differences of >0.2 relative to matched controls. The 5 
CpGs comprised of 5 genes (COPS8, PIK3R5, HAAO, C5orf34, and CCDC124) and 
their functions are shown in Table 1. 
 
Discussion 
We describe for the first time, genome-wide DNA methylation changes in maternal 
blood prior to the diagnosis of GDM. We identified 2 differentially methylated genes 
that shared identity with genes previously described in studies that interrogated 
placenta and umbilical cord blood samples and, in these cases, using the same array 
platforms.17, 22 Furthermore, using stringent filtering criteria, we identified 100 unique 
CpGs that segregated GDM and healthy pregnancies into distinct groups upon 
hierarchical clustering.  
 
The strength of our study, in contrast to previous studies, is that we carefully matched 
each GDM pregnancy to a healthy one to ensure the samples were comparable.17, 22 
Furthermore, as all samples were taken prior to development of pregnancy 
complications, there was limited sampling bias. 
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We were able to compare our data to those from two recent genome-wide studies in 
GDM using cord blood and placenta tissue.17, 22 Comparative analysis with Finer et 
al.22 showed that HOOK2 and RDH12 were common to maternal blood, placenta and 
cord blood. HOOK2 codes for a linker protein that mediates binding to organelles and 
is responsible for morphogenesis of cilia and endocytosis.27, 28,29 RDH12 encodes a 
retinal reductase, which also plays a role in the metabolism of short-chain 
aldehydes.27, 30 In terms of KEGG orthology, it is involved in metabolic pathways as 
well as retinal metabolism.31 These two genes, therefore, may represent important 
candidates for further study.   
 
The disparity of candidate genes when comparisons are made to the previous studies 
might reflect the different data filtering criteria used by Ruchat et al. 17 and Finer et 
al.22 Using the Finer et al. criteria, many of the differentially methylated CpGs are 
likely to have β-value differences <0.2, which could be difficult to reproduce either by 
alternative methodologies, such as pyrosequencing or in replication studies using 
independent patient cohorts. Moreover, we used a distinct patient population to the 
other two studies. We used samples from women prior to the development of their 
GDM, while both Ruchat et al.17 and Finer et al.22 used samples from women with 
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established GDM. Furthermore, we used maternal blood samples, rather than 
placenta and cord blood samples. These disparities may have contributed to the 
differences in the absolute numbers of CpGs/genes identified. 
 
Further analysis of our cohort identified 100 independent CpGs (comprising 66 genes), 
which were found to cluster GDM and healthy pregnancies separately. Reassuringly, 
these CpGs have no annotated SNPs in the probe. Enrichment of gene ontology 
terms and biological pathways of these 66 genes showed enrichment for genes 
involved in cell adhesion, type 1 diabetes mellitus, and keratin pathways.26, 32 
Although the enrichment was not statistically significant following adjustment for false 
discovery rates, these are promising candidates, which are worth examining to 
elucidate the biological mechanisms behind GDM. In future work, it will be important 
to verify, in larger independent cohorts, the candidates identified herein and to 
determine the impact of differential methylation. This may in the future improve the 
understanding of GDM pathogenesis and aid in the development of therapy. 
 
The design of this pilot study was to generate a list of genes of interest using a 
relatively small number of samples. In order to avoid type II errors (false negatives), 
we used uncorrected P-values to identify potential candidates in the preliminary 
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screening. We then applied more stringent methodology (steps 2-4 of Figure 1) to 
identify candidate genes. A potential limitation of our study is the possibility of 
genomic inflation. Mild confounding stratification factors, such as changes in 
composition of blood during the pregnancy, the time of blood sampling, and parity, 
may have inflated the data. Therefore, we further validated the array data using an 
independent method with pyrosequencing in order to confirm our findings. 
 
On closer inspection, 8 of 11 women who subsequently developed GDM showed 
differential methylation at 5 CpGs (consisting of COPS8, PIK3R5, HAAO, CCDC124, 
and C5orf34 genes) relative to matched controls. COPS8 encodes a regulator of 
multiple signaling pathways.27, 33 It is involved in protein binding and negative 
regulation of cell proliferation.33, 34 The PIK3R5 protein has important roles in cell 
growth, proliferation, motility, differentiation, survival, and intracellular trafficking.27, 
35-37 The HAAO protein catalyzes the synthesis of quinolinic acid (QUIN). Increased 
cerebral levels of QUIN may participate in the pathogenesis of neurologic and 
inflammatory disorders, which may be mediated by HAAO.27, 38 This unique epigenetic 
signature may form the basis of future biomarker studies using a larger validation 
cohort. The CCDC124 protein is involved in cell cycle and division.39 C5orf34 encodes 
for a protein that is highly conserved across species; however, its function remains 
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uncharacterised.27  
 
In summary, for the first time, using a genome-wide approach in maternal blood, we 
have identified maternal methylation changes prior to the diagnosis of GDM. As a 
discovery-based study, our findings may prove useful towards developing simple 
biomarkers for predicting GDM, thus facilitating intervention strategies in the early 
antenatal period to improve the health of the mother and baby, both during pregnancy 
and in the long-term. 
 
Materials and Methods 
Patients 
Peripheral blood samples were obtained from women prospectively recruited at the 
University Hospital of North Midlands, UK, between 12-16 weeks gestation, prior to 
the diagnosis of any pregnancy complications as part of the EFFECT-M study.40 At the 
end of pregnancy, we identified 11 women who had GDM and individually matched 
each one with a healthy woman who had a normal pregnancy. They were matched in 
terms of age, body mass index, ethnicity, smoking status, medications and folate 
supplementation (Table S3). The study was approved by the West Midlands (Black 
Country) Research Ethics Committee (REC reference no. 08/H1204/121). 
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Genome-wide DNA methylation profiling 
We performed genome-wide analysis of DNA methylation using the Illumina 
HumanMethylation450 BeadChip (450K) array, which examines over 480,000 
individual CpG sites. We first extracted genomic DNA from blood samples collected 
into potassium EDTA using standard phenol/chloroform procedures. Next, samples 
were sodium bisulfite converted 41 and hybridized to arrays according to Illumina 
recommended protocols that we have previously described.42 Methylation at 
individual CpGs is reported as a methylation β-value, which is a quantitative measure 
of methylation for each CpG site with range between 0 (no methylation) to 1 
(completely methylated).  
 
Validation by sodium bisulfite pyrosequencing 
A technical validation between array β-values and methylation levels was determined 
by sodium bisulfite pyrosequencing in all 22 samples. To increase template quantity 
for pyrosequencing assays, whole genome amplification of bisulfite-converted DNA 
followed by touchdown PCR were performed as previously described.42 A PyroMark 
Q24 instrument was used to run pyrosequencing assays according to the 
manufacturer’s instructions (Qiagen). Analyses of Pyrograms were conducted on the 
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PyroMark Q24 software (v 2.0.6., build 20; Qiagen). Seven CpGs representing 5 
genes were chosen to provide a range of β-values. These demonstrated a strong 
positive correlation between β-values and percentage methylation by bisulphite 
sequencing (Spearman’s r = 0.92, Figure S2). 
 
Data analysis 
Each array passed quality control assessment based on the performance of internal 
array controls. Initial processing, probe type correction and assessment of array data 
was conducted using the minfi package and SWAN.23, 24 Probes with known SNPs 
were removed. All CpGs for which one or more of the 22 samples displayed detection 
P-values > 0.05 (indicating an unreliable site) or presented with missing β-values 
were excluded. The genomic inflation factor (λ, the ratio of the median of the observed 
distribution of the test statistic to the expected median) was calculated using the 
estlambda function of GenABEL.25 
 
We filtered the data using criteria shown in Figure 1 to identify differentially 
methylated sites between GDM and healthy pregnancies. In step the first analysis, we 
elected to use a minimum β-value difference of 0.05, in part to permit comparisons 
with a recent report describing DNA methylation in placenta and umbilical cord blood 
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from GDM pregnancies also using the 450K array platform (step 1, Figure 1).22 The 
genes identified as differentially methylated were obtained from the supplementary 
data of this particular publication. We also compared our data with a separate cohort 
of placenta and umbilical cord blood samples from GDM pregnancies.17 We obtained 
their list of differentially methylated genes through personal communication with the 
corresponding author of the publication. Further filtering steps were applied to 
facilitate a more stringent analysis. To reduce the number of non-variable sites to 
improve the statistical power of subsequent analyses, we removed all sites with 
β-values ≥0.8 and ≤0.2 in all 22 samples (step 2, Figure 1). This is an approach that 
has been used by our group as well as by others.41-44 As described previously by our 
group, we consider it a more robust methodology to remove from the data set CpGs 
that failed in any one of the samples, instead of eliminating specific failed CpGs from 
specific samples.42 We retained only those CpGs that had a mean β-value difference 
of ≥0.2 (step 3, Figure 1). Finally we examined the absolute β-values in each matched 
pairs. We used a cut-off of ≥0.2 mean β-values difference to identify CpGs with 
considerable methylation differences. 
 
Hierarchical clustering was performed utilizing Genesis software (v1.7.6) using 
Euclidian distance and average linkage criteria.45 Enrichment of gene ontology terms 
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and biological pathways within the genes associated with differentially methylated 
CpGs were assessed using DAVID online software. 26, 32 
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Table 1. Annotation for the 5 genes differentially methylated in 8 of 11 matched pairs, 
as determined by genome-wide DNA methylation analysis. *The official gene symbol, 
gene name and stated function were retrieved from the NCBI Gene database 
(accessed September 2015). **The absolute β-value difference range is the minimum 
to the maximum value of the individual absolute β-value differences for each 
differentially methylated CpG. 
Gene 
symbol* 
Absolute β-value 
difference 
range** 
Gene name* Functional 
summary 
COPS8 0.05-0.84 
 
Constitutive 
photomorphogenic 
homolog subunit 8 
Regulator of multiple 
signaling pathways 
PIK3R5 0.02-0.82 
 
Phosphoinositide-3-kinase, 
regulatory subunit 5 
Cell growth, 
proliferation, 
differentiation, 
motility, survival, and 
intracellular 
trafficking 
HAAO 0.02-0.77 3-hydroxyanthranilate Catalyses the 
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 3,4-dioxygenase synthesis of 
quinolinic acid 
(QUIN), which is 
an excitotoxin that 
may participate in the 
pathogenesis of 
neurologic and 
inflammatory 
disorders 
CCDC124 0.01-0.79 
 
Coiled-coil domain 
containing 124 
Cell cycle, cell 
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Figure 1. Filtering criteria for the identification of CpGs differentially methylated 
between GDM and normal pregnancies. The starting number of CpGs (484,273) was 
derived through the removal of CpGs with high detection values (p >0.05) and those 
with missing β-values in any one of the 22 samples, as described in the Materials and 
Methods. Horizontal line denotes additional filtering steps. *According to Finer et al. 
criteria.22 **According to Ruchat et al. criteria.17 GDM, gestational diabetes. SD, 
standard deviation. 
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Figure 2. Venn diagrams illustrating comparison of genes differentially methylated in 
GDM using maternal blood with those identified in cord blood and placenta of GDM 
affected pregnancies from the cohorts of (A) Finer et al.22 and (B) Ruchat et al.17, 
respectively. The genes from our dataset that were common with the other study are 
shown in dark gray shading. Genes identified as differentially methylated in Finer et 
al.22 were obtained from Supplementary file 2 of the published article, while the list of 
differentially methylated genes identified by Ruchat et al.17 was kindly provided 
through personal communication with the corresponding author of Ruchat et al.17 
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Figure 3. Heatmap and dendrograms showing clustering45 for the 100 CpGs 
identified as differentially methylated (mean difference in β-values >0.2) between 
GDM and healthy pregnancies. DNA methylation across the 100 sites in each of the 
samples was analysed by hierarchical clustering using the Euclidean distance and 
average linkage criteria. Each row represents an individual CpG site and each 
column a different sample. Healthy controls and GDM samples are shown by the 
green and red bars, respectively. Slide type is also shown with slide 1 in green and 
slide 2 in red. Color gradation from yellow to blue represents low to high DNA 
methylation respectively, with β-values ranging from 0 (no methylation; yellow) to 1 
(complete methylation; blue). GDM, gestational diabetes. 
 
 
